

Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 8, 1987

Contents

PAUL L. CANNER, LAËL C. GATEWOOD, COLIN WHITE, JOHN M. LACHIN, and LESLIE J. SCHOENFIELD	
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study	1
R. BRIAN HAYNES and RENATO DANTES	
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials	12
SAM WIEAND and TERRY THERNEAU	
A Two-Stage Design for Randomized Trials with Binary Outcomes	20
BARRY W. BROWN, JAY HERSON, E. NEELY ATKINSON, and M. ELIZABETH ROZELL	
Projection from Previous Studies: A Bayesian and Frequentist Compromise	29
CARINA HEISELBETZ and LUTZ EDLER	
A Sample Size Program for "Proving the Null Hypothesis"	45
G. ROSS LANGLEY, HEATHER J. SUTHERLAND, SAMUEL WONG, SALOMON MINKIN, HILARY A. LLEWELLYN-THOMAS, and JAMES E. TILL	
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?	49
JOHN A. BLESSING, BRIAN N. BUNDY, PETER A. REESE, and ROGER L. PRIORE	
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group)	60
PER KRAGH ANDERSEN	
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial	67
BARBARA S. HAWKINS	
Perusing the Literature	75
Book Review	85
Announcements	

BLOSSOM H. PATTERSON	
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials	87
E. van der PUTTEN, J. W. van der VELDEN, A. SIERS, and E. A. M. HAMERSMA, for the Cooperative Study Group of Dutch Datamanagers	
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial	96
CLAIR HAAKenson, CAROL L. FYE, MIKE R. SATHER, and DENNIS J. TOUSSAINT	
The Investigator-Sponsored IND in Clinical Trials	101
BARRY R. DAVIS, J. DAVID CURB, BETTY TUNG, C. MORTON HAWKINS, SCOTT EHHRMAN, JOHN FARMER, and MICHAEL MARTIN	
Standardized Physician Preparation of Death Certificates	110
LESLIE A. KALISH and COLIN B. BEGG	
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias	121
J. M. LONG, J. R. SLAGLE, A. S. LEON, M. W. WICK, J. P. MATTS, J. N. KARNEGIS, J. K. BISSETT, H. S. SAWIN, and J. P. STEVENSON	
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data	136
L. DOUGLAS CASE, TIMOTHY M. MORGAN, and C. E. DAVIS	
Optimal Restricted Two-Stage Designs	146
Letter to the Editor	157
BARBARA S. HAWKINS	
Perusing the Literature	158
Announcement	175
JERRY HALPERN and BYRON WM. BROWN, JR.	
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test	177
PETER PEDUZZI, H. TERESA HATCH, GARY JOHNSON, ANN CHARBONEAU, JOYCE PRITCHETT, and KATHERINE DETRE	
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery	190
STEVEN PIANTADOSI and BLOSSOM PATTERSON	
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials	202
DAVID WATERS, DONNA FREEDMAN, JACQUES LESPERANCE, PIERRE THEROUX, LISE LEMARBRE, BARBARA KAMM, MICHEL JOYAL, IHOR DYRDA, GILBERT GOSELIN, GILLES HUDON, MARILYN HACHE, JUDITH HALLORAN, and RICHARD J. HAVEL	
Design Features of a Controlled Clinical Trial to Assess the Effect of a Calcium Entry Blocker Upon the Progression of Coronary Artery Disease	216
ALAN LEVITON, JENNY BAGLIVO, KARL C.K. KUBAN, ELIZABETH R. BROWN, and KALPATHY C. KRISHNAMOORTHY	
The Prophylactic Clinical Trial as an Epidemiologic Resource	243

BARBARA S. HAWKINS Perusing the Literature	255
Society for Clinical Trials: Officers, Board of Directors, Program Committee, and Secretariat	266
Final Program: Eighth Annual Meeting of the Society for Clinical Trials	267
Abstracts: Eighth Annual Meeting of the Society for Clinical Trials	280
Announcement: Ninth Annual Meeting for the Society for Clinical Trials	313
M. HALPERIN, K.K.G. LAN, E.C. WRIGHT, and M.A. FOULKES Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies	315
ANNE I. GOLDMAN Issues in Designing Sequential Stopping Rules for Monitoring Side Effects in Clinical Trials	327
MICHAEL PHILLIPS and ALFREDO J. VAZQUEZ Abnormal Findings in "Normal" Research Volunteers	338
K. DICKERSIN, S. CHAN, T.C. CHALMERS, H.S. SACKS, and H. SMITH, JR. Publication Bias and Clinical Trials	343
DAVID H. BLANKENHORN, RUTH L. JOHNSON, SHARON A. NESSIM, STANLEY P. AZEN, MIGUEL E. SANMARCO, ROBERT H. SELZER, and the CLAS INVESTIGATORS and STAFF The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results	354
IAN CHALMERS and WILLIAM SILVERMAN Commentary: Professional and Public Double Standards on Clinical Experimentation	388
Letters to the Editor	392
BARBARA S. HAWKINS Perusing the Literature	395
Book Reviews	404
Announcement	411
Author Index to Volume 8	413
Subject Index to Volume 8	414
Volume Contents	